MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

EyePoint, Inc. - Common Stock (NQ:EYPT)

4.435 -0.065 (-1.44%)
Streaming Delayed Price Updated: 1:45 PM EDT, Sep 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,282,624
Open 4.400
Bid (Size) 4.430 (700)
Ask (Size) 4.440 (800)
Prev. Close 4.500
Today's Range 4.350 - 4.550
52wk Range 3.950 - 19.11
Shares Outstanding 34,984,044
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Kessler Topaz Meltzer & Check, LLP Encourages EyePoint, Inc. (NASDAQ: EYPT) Investors to Contact the Firm
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
News headline image
NASDAQ: EYPT: Kessler Topaz Meltzer & Check, LLP Launches Investigation Into EyePoint, Inc.
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire

Performance

YTD
-74.6%
-74.6%
1 Month
-64.3%
-64.3%
3 Month
-66.3%
-66.3%
6 Month
-75.8%
-75.8%
1 Year
-62.2%
-62.2%

More News

Read More
News headline image
EYPT Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages EYPT Investors With Losses to Contact the Firm
Via NewMediaWire
News headline image
EYPT Investors Have Opportunity to Join EyePoint, Inc. Fraud Investigation with SBS Law
From Schall, Brown & Schwartz LLP
Via Business Wire
EyePoint (NASDAQ:EYPT) Rallies Despite Wider Q2 Loss as Phase 3 Data Nears ↗
Via Chartmill
EyePoint Inc. (NASDAQ:EYPT) Revenue Beats Estimates, Earnings Miss in Q1 2026 Report ↗
Via Chartmill
Topics Earnings
News headline image
NASDAQ: EYPT Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages EyePoint, Inc. (NASDAQ: EYPT) Investors to Contact the Firm
From Kessler Topaz Meltzer & Check, LLP
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT
From Pomerantz LLP
Via GlobeNewswire
News headline image
EYPT Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into EyePoint Pharmaceuticals (EYPT)
From Levi & Korsinsky, LLP
Via Business Wire
Let's take a look at the stocks that are in motion in today's session. ↗
Via Chartmill
Let's have a look at the top gainers and losers in the middle of the day of today's session. ↗
Via Chartmill
News headline image
EyePoint’s DURAVYU Misses Primary Endpoint in Phase III Wet AMD Trial ↗
Via MarketBeat
There are notable gap-ups and gap-downs in today's session. ↗
Via Chartmill
These stocks are moving in today's pre-market session ↗
Via Chartmill
News headline image
Will SpaceX Stock Double Anytime Soon? No -- but These 3 Stocks Could ↗
Via The Motley Fool
News headline image
EyePoint Pharmaceuticals Eyes Transformative 2026 as DURAVYU Phase 3 Data Nears ↗
Via MarketBeat
News headline image
Alumis Stock Has Soared 400%. Cormorant Bought Another $8 Million Last Quarter ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why This Fund Just Made a $55 Million Bet on Dianthus Amid a 350% Stock Rally ↗
Via The Motley Fool
News headline image
Erasca Stock Is Up 715%. Here’s Why One Biotech Fund Still Bought $68 Million More ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
EyePoint (EYPT) Q1 2026 Earnings Transcript ↗
Via The Motley Fool
News headline image
This Fund Bought $28 Million of a Beaten-Down Immunotherapy Stock Last Quarter. What Should Long-Term Investors Know? ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This $64 Million Biotech Exit Seemingly Missed a 77% One-Day Surge on Gilead Takeover Deal ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Biotech Stock Up Nearly 300% Draws $68.7 Million Bet as Breast Cancer Drug Targets 2027 Launch ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Biotech Stock Up 700% Is Still a Top Holding Despite a $9.3 Million Sale Last Quarter ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Biotech Stock Up Nearly 100% in a Year Has Drawn a New $20 Million Share Investment ↗
Via The Motley Fool

Frequently Asked Questions

Is EyePoint, Inc. - Common Stock publicly traded?
Yes, EyePoint, Inc. - Common Stock is publicly traded.
What exchange does EyePoint, Inc. - Common Stock trade on?
EyePoint, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for EyePoint, Inc. - Common Stock?
The ticker symbol for EyePoint, Inc. - Common Stock is EYPT on the Nasdaq Stock Market
What is the current price of EyePoint, Inc. - Common Stock?
The current price of EyePoint, Inc. - Common Stock is 4.435
When was EyePoint, Inc. - Common Stock last traded?
The last trade of EyePoint, Inc. - Common Stock was at 09/01/26 01:45 PM ET
What is the market capitalization of EyePoint, Inc. - Common Stock?
The market capitalization of EyePoint, Inc. - Common Stock is 155.15M
How many shares of EyePoint, Inc. - Common Stock are outstanding?
EyePoint, Inc. - Common Stock has 155M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story